This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

JOEL B. CHODOS, M.D.; HEDWIGE E. HABEGGER-CHODOS, M.D.

Arch Ophthalmol. 1961;65(3):401-409.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Introduction

Uveitis of toxoplasmic origin has been treated until the present time by a combination of pyrimethamine (Daraprim) and sulfonamide. At the onset of therapy, elevated doses of pyrimethamine ranging up to 200 mg. on the first day are required in order to reach and maintain effective blood levels¹ within a short period. This regimen is often accompanied by headache, nausea, and vomiting which usually subside. However, many patients complain of persistent headache and a general feeling of ill-being. In addition, high doses of bicarbonate are given to keep the urine alkaline and prevent crystallization of the sulfonamide in the renal tubules. The number of tablets to be swallowed and the ensuing side-effects often discourage the patient from scrupulously carrying out the prescribed treatment for 6 to 8 weeks. Therapy is often discontinued because of leukopenia or thrombocytopenia.² The tendency of steroids to retain water and the necessity . . . [Full Text PDF of this Article]

Author Affiliations
Philadelphia

Wills Eye Hospital and Graduate School of Medicine, University of Pennsylvania, Philadelphia.

Footnotes
Submitted for publication Sept. 30, 1960.

This study was supported by a grant from the Hartford Foundation.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?